Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Everolimus and Basiliximab Permit Suppression by Human CD4+CD25+ Cells in vitro

1 Mar 2005

Abstract excerpt

Immunosuppressive drugs are essential for the prevention of acute transplant rejection but some may not promote long-term tolerance. Tolerance is dependent on the presence and regulatory function of CD4(+)CD25(+) T cells in a number of animal models. The direct effects of immunosuppressive drugs on CD4(+)CD25(+) cells, particularly those that interfere with IL-2 signaling are uncertain. We studied the effects of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Immune Cell Function and Interaction
Share to Pancreatic function and diabetes
Share to Renal Transplantation Outcomes and Treatments

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 15707399
DOI: 10.1111/j.1600-6143.2005.00758.x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Everolimus and Basiliximab Permit Suppression by Human CD4+CD25+ Cells in vitroPMID 15707399Read ↗

Selective survival of naturally occurring human CD4+CD25+Foxp3+ regulatory T cells cultured with rapamycin.Semantic proximity Read ↗

Human CD25+CD4+ T Suppressor Cell Clones Produce Transforming Growth Factor β, but not Interleukin 10, and Are Distinct from Type 1 T Regulatory CellsSemantic proximity Read ↗

CD4+CD25+ Immunoregulatory T CellsSemantic proximity Read ↗

The time is crucial for ex vivo expansion of T regulatory cells for therapy.Semantic proximity Read ↗

In vitro expanded human CD4+CD25+ regulatory T cells are potent suppressors of T-cell-mediated xenogeneic responses.Semantic proximity Read ↗

The immunosuppressive effects of human bone marrow-derived mesenchymal stem cells target T cell proliferation but not its effector functionSemantic proximity Read ↗

Regulatory T-cells in antitumor therapy: isolation and functional testing of CD4+CD25+ regulatory T-cells.Semantic proximity Read ↗

CD4+ regulatory T cells are spared from deletion by antilymphocyte serum, a polyclonal anti-T cell antibody.Semantic proximity Read ↗

Treatment with bortezomib of human CD4+ T cells preserves natural regulatory T cells and allows the emergence of a distinct suppressor T-cell population.Semantic proximity Read ↗

T regulatory cells control T‐cell proliferation partly by the release of soluble CD25 in patients with B‐cell malignanciesSemantic proximity Read ↗

Ex vivo expanded human CD4+CD25+Foxp3+ regulatory T cells prevent lethal xenogenic graft versus host disease (GVHD)Semantic proximity Read ↗

Expansion of human regulatory T-cells from patients with type 1 diabetes.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.